- Home
- TRIP vs IMTX Comparison
TRIP vs IMTX Comparison
Compare TRIP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | IMTX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRIP | IMTX |
|---|---|---|
| Price | $8.93 | $8.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $14.40 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 3.5M | 572.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,556,000,000.00 | N/A |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $5.12 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.41 | $6.55 |
| 52 Week High | $19.45 | $12.41 |
Technical Indicators
Market Signals| Indicator | TRIP | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.72 | 38.81 |
| Support Level | $8.41 | $8.37 |
| Resistance Level | $11.76 | $10.51 |
| Average True Range (ATR) | 0.35 | 0.36 |
| MACD | 0.09 | -0.07 |
| Stochastic Oscillator | 35.74 | 15.13 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025. The company is selling TheFork, its dining brand, which represented 12% of sales.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.